drug_type
RELEVANT_DRUG
intervention_type
Autologous gene-modified cellular immunotherapy
drug_description
Autologous patient T cells engineered to express a chimeric antigen receptor targeting CD19 on B cells; CAR engagement activates cytotoxic T-cell responses (activation, expansion, cytokine release, perforin/granzyme-mediated killing) to eliminate CD19+ malignant B cells and can cause on-target B-cell aplasia in pediatric r/r B-ALL.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous patient T cells are engineered to express a chimeric antigen receptor that recognizes CD19 on B cells. CAR engagement triggers T-cell activation, proliferation, cytokine release, and perforin/granzyme-mediated cytotoxic killing of CD19-positive malignant B cells, often leading to on-target B-cell aplasia.
drug_name
anti-CD19 CAR T-cell therapy
nct_id_drug_ref
NCT06635330